NanoInk, Inc., an emerging growth technology company specializing in nanometer-scale manufacturing and applications development in the life sciences and semiconductor industries, announced today that it has been awarded a $735,000 Phase II Small Business Innovation Research (SBIR) grant from the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH). The Grant will be used to develop novel, biologically functional nanostructures that dramatically enhance the reproducibility, sensitivity, and spatial density of chip-based assays.
